Omega-3 Fatty Acids in Patients with ASCVD Risk- The Role of Icosapent Ethyl (IPE)
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Omega-3 Fatty Acids in Patients with ASCVD Risk- The Role of Icosapent Ethyl (IPE)

Industry Essentials organised by Medtelligence, Inc. and sponsored by Amarin, Inc.

medtelligence_logo.jpgamarin-logo.jpg
Title
Speaker
Slides
Video
Q&A
  • Title: Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD
    Speaker: M Farnier (Fixin,FR)

    NA

    Video:

    Q&A:
     
  • Title: Mechanisms and Comparisons of Omega-3s.
    Speaker: B Nordestgaard (Herlev,DK)

    NA

    Video:

    Q&A:
     

 

The content of these presentations reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

 

  Back to the Industry Essentials

About the ESC
Press and Media
Information
Follow us

         

 Need help?

 Help centre
 Contact us

© 2025 European Society of Cardiology. All rights reserved.